13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002005245
Total reported value
$4.9B
$4.9B
116 檔
13.0%
The Q1 2025 SEC filing reveals that Siren, L.L.C. held a total portfolio value of $4.9B, covering 116 public equity positions.
During Q1 2025, Siren, L.L.C.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SRRK, ONC, KYMR) accounted for 13.0% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding CORP | Stock-Other | 16.78% | -4.09% | — | |
| 2 | ONC | Beone Medicines Ltd-adr | Stock-Other | 7.66% | -1.15% | -23.72% | |
| 3 | KYMR | Kymera Therapeutics Inc | Stock-Other | 5.00% | -0.55% | +9.11% | |
| 4 | 2655787D | Blueprint Medicines CORP | Stock-Other | 3.63% | — | — | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.19% | -0.84% | +4.91% | |
| 6 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.18% | — | -8.45% | |
| 7 | IRON | Disc Medicine Inc | Stock-Other | 3.00% | -0.43% | — | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.93% | — | +106.74% | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 2.53% | — | -3.35% | |
| 10 | ✓ | Merus N V | Stock-Other | 2.48% | — | +33.03% | |
| 11 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.40% | +0.17% | -0.18% | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.40% | -1.16% | EXIT | |
| 13 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.21% | — | -8.76% | |
| 14 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.11% | -1.25% | +131.02% | |
| 15 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.92% | +0.02% | -7.99% | |
| 16 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.85% | — | -1.48% | |
| 17 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.68% | -0.49% | EXIT | |
| 18 | TBLA | Taboola.com Ltd. | Stock-Other | 1.66% | -0.01% | — | |
| 19 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.60% | -0.16% | +101.71% | |
| 20 | SLDB | Solid Biosciences Inc | Stock-Other | 1.55% | +0.02% | +97.81% | |
| 21 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.39% | -0.52% | -1.48% | |
| 22 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.25% | — | -20.38% | |
| 23 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.12% | +0.41% | -1.36% | |
| 24 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.02% | +0.08% | -1.45% | |
| 25 | VERA | Vera Therapeutics Inc | Stock-Other | 1.01% | — | -1.48% | |
| 26 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 1.01% | +0.23% | — | |
| 27 | PRTA | Prothena Corporation plc | Stock-Other | 0.90% | — | +16.70% | |
| 28 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.87% | -0.20% | EXIT | |
| 29 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.84% | -0.48% | +12.37% | |
| 30 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.83% | +0.80% | — | |
| 31 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 32 | SEPN | Septerna Inc | Stock-Other | 0.72% | -0.04% | — | |
| 33 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.71% | -0.29% | — | |
| 34 | IHS | IHS Holding Limited | Stock-Other | 0.69% | — | — | |
| 35 | ERAS | Erasca Inc | Stock-Other | 0.68% | -0.81% | -1.13% | |
| 36 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.63% | -0.01% | -1.50% | |
| 37 | PCVX | Vaxcyte Inc | Stock-Other | 0.63% | — | -1.48% | |
| 38 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 0.61% | -0.11% | +54.79% | |
| 39 | MSFT | Microsoft CORP | Stock-Tech | 0.60% | +0.04% | +23.91% | |
| 40 | RELY | Remitly Global Inc | Stock-Other | 0.58% | +0.03% | — | |
| 41 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.51% | +0.27% | -1.33% | |
| 42 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.51% | +0.23% | -1.48% | |
| 43 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 0.50% | -0.10% | +4.17% | |
| 44 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.44% | +0.31% | -1.48% | |
| 45 | GOOGL | Alphabet Inc-cl A | Stock-Comm Services | 0.44% | +0.13% | +624.33% | |
| 46 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 0.42% | — | -1.57% | |
| 47 | ADBE | Adobe Inc | Stock-Tech | 0.42% | — | +119.35% | |
| 48 | KRRO | Korro Bio Inc | Stock-Other | 0.41% | -0.02% | — | |
| 49 | NOW | Servicenow Inc | Stock-Tech | 0.41% | -0.05% | +62.82% | |
| 50 | SEER | Seer Inc | Stock-Other | 0.38% | -0.03% | — |
According to official SEC Form 13F filings, Siren, L.L.C. reported a total U.S. public equity portfolio value of $4.9B across 116 disclosed positions in Q1 2025.
During Q1 2025, Siren, L.L.C.'s top holdings by market value included SRRK (16.8%)、ONC (7.7%)、KYMR (5.0%). The largest single position, SRRK, represented 16.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q1 2025, Siren, L.L.C. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.